Diagnostic Tests

Biomarkers/Diagnostic Tests

To date, no biomarker or diagnostic test has been adopted by the scientific community or healthcare industry. The below is a brief review of potential tests that might be used for ME/CFS diagnosis in the future. This is not a complete listing.

Immunological Tests
- Electrophysiological properties of PBMCs (Clarke 2023):
  The dielectric and ζ-potential response of PBMCs to 1.5-hour hyperosmotic challenge differentiated ME/CFS donors from healthy controls with 81.80% sensitivity and 85.70% specificity.
- EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling (Hunter 2025):
  Whole-genome 3D DNA screening for chromosome conformations correlated to ME/CFS diagnosis, resulting in a 200-marker model for ME/CFS diagnosis (Episwitch®CFS test). First testing on the retrospective independent validation cohort demonstrated a strong systemic ME/CFS signal with a sensitivity of 92% and a specificity of 98%.
Autonomic & Cardiopulmonary Tests
- iCPET?
- Cerebral blood flow?
- Hand Grip?
Other Tests
- SMPDL3B can identify subclinical kidney impairment in ME/CFS (Rostami-Afshari 2025)